Literature DB >> 34152690

COVID-19 and the liver: A 2021 update.

Catherine W Spearman1, Alessio Aghemo2,3, Luca Valenti4,5, Mark W Sonderup1.   

Abstract

In December 2019, a novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was identified in Wuhan, China and has since resulted in a global pandemic in excess of 165 million reported infections and 3.4 million attributable deaths. COVID-19 is primarily a respiratory illness, which may be complicated by pneumonia and acute respiratory distress syndrome. SARS-CoV-2 is also responsible for numerous extrapulmonary manifestations involving the haematologic, cardiovascular, renal, gastrointestinal and hepatobiliary, endocrinologic, neurologic, ophthalmologic and dermatologic systems. This review will discuss the pathophysiology of COVID-19; focusing on the mechanisms and outcomes of liver injury associated with COVID-19; its impact on chronic liver disease (CLD); management of CLD during the COVID-19 pandemic and the long-term impact of COVID-19 on CLD.
© 2021 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  COVID-19; SARS-CoV-2; liver disease; liver injury; liver transplantation

Year:  2021        PMID: 34152690     DOI: 10.1111/liv.14984

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  8 in total

1.  Prevalence of abnormal liver biochemistry and its impact on COVID-19 patients' outcomes: a single-center Greek study.

Authors:  Evangelos Cholongitas; Triada Bali; Vasiliki E Georgakopoulou; Alexios Giannakodimos; Argyrios Gyftopoulos; Vasiliki Georgilaki; Dimitrios Gerogiannis; Dimitrios Basoulis; Irene Eliadi; Georgios Karamanakos; Konstantinos Mimidis; Nikolaos V Sipsas; Michael Samarkos
Journal:  Ann Gastroenterol       Date:  2022-03-25

2.  Liver Injury and Elevated Levels of Interleukins, Interleukin-2 Receptor, and Interleukin-6 Predict the Severity in Patients With COVID-19.

Authors:  Kuan Luo; Yongfeng Chen; Junjie Yang; Quan Tao; Min Luo
Journal:  Front Public Health       Date:  2021-12-14

3.  Antibody Responses after SARS-CoV-2 Vaccination in Patients with Liver Diseases.

Authors:  Athanasios-Dimitrios Bakasis; Kleopatra Bitzogli; Dimitrios Mouziouras; Abraham Pouliakis; Maria Roumpoutsou; Andreas V Goules; Theodoros Androutsakos
Journal:  Viruses       Date:  2022-01-21       Impact factor: 5.048

Review 4.  Long-term complications of COVID-19.

Authors:  Amar D Desai; Michael Lavelle; Brian C Boursiquot; Elaine Y Wan
Journal:  Am J Physiol Cell Physiol       Date:  2021-11-24       Impact factor: 4.249

5.  Safety and Humoral and Cellular Immunogenicity of the BNT162b2 SARS-CoV-2 Vaccine in Liver-Transplanted Adolescents Compared to Healthy Adolescents.

Authors:  Palittiya Sintusek; Supranee Buranapraditkun; Siriporn Khunsri; Varattaya Saengchaisukhonkit; Preeyaporn Vichaiwattana; Donchida Srimuan; Thanunrat Thongmee; Yong Poovorawan
Journal:  Vaccines (Basel)       Date:  2022-08-16

6.  Sars-Cov-2 vaccination in liver transplant recipients: The 'holy grail' in a hostile environment.

Authors:  Patrizia Burra; Francesco Paolo Russo
Journal:  Liver Int       Date:  2022-06       Impact factor: 8.754

7.  Humoral Immunogenicity to SARS-CoV-2 Vaccination in Liver Transplant Recipients: A Systematic Review and Meta-Analysis.

Authors:  Jeong-Ju Yoo; Dong Keon Yon; Seung Won Lee; Jae Il Shin; Beom Kyung Kim
Journal:  Int J Biol Sci       Date:  2022-09-21       Impact factor: 10.750

8.  Aspartate aminotransferase in COVID-19: A probably overrated marker.

Authors:  Elena Aloisio; Mauro Panteghini
Journal:  Liver Int       Date:  2021-10-05       Impact factor: 5.828

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.